{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:47:58Z","timestamp":1785754078775,"version":"3.56.0"},"reference-count":84,"publisher":"Informa UK Limited","issue":"8","license":[{"start":{"date-parts":[[2026,3,16]],"date-time":"2026-03-16T00:00:00Z","timestamp":1773619200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Review of Anticancer Therapy"],"published-print":{"date-parts":[[2026,8,3]]},"DOI":"10.1080\/14737140.2026.2645395","type":"journal-article","created":{"date-parts":[[2026,3,12]],"date-time":"2026-03-12T10:44:58Z","timestamp":1773312298000},"page":"977-985","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Mirdametinib in symptomatic neurofibromatosis type 1 plexiform neurofibromas"],"prefix":"10.1080","volume":"26","author":[{"given":"Kester A.","family":"Phillips","sequence":"first","affiliation":[{"name":"HealthPartners Cancer Center at Regions Hospital","place":["St. Paul, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Schiff","sequence":"additional","affiliation":[{"name":"University of Virginia Health System","place":["Charlottesville, USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,3,16]]},"reference":[{"key":"e_1_3_5_3_1","doi-asserted-by":"publisher","DOI":"10.1542\/peds.2007-3204"},{"key":"e_1_3_5_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1096-8628(19990326)89:1<31::AID-AJMG7>3.0.CO;2-W"},{"key":"e_1_3_5_5_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15041217"},{"key":"e_1_3_5_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.08.051"},{"key":"e_1_3_5_7_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev-pathol-011811-132441"},{"key":"e_1_3_5_8_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000250332.89420.e6"},{"key":"e_1_3_5_9_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaa053"},{"key":"e_1_3_5_10_1","doi-asserted-by":"publisher","DOI":"10.1186\/1750-1172-7-75"},{"key":"e_1_3_5_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jpeds.2011.04.008"},{"key":"e_1_3_5_12_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e3181bd1326"},{"key":"e_1_3_5_13_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17010123"},{"key":"e_1_3_5_14_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noy067"},{"key":"e_1_3_5_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/ceo.12179"},{"key":"e_1_3_5_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2013.01.011"},{"key":"e_1_3_5_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ophtha.2012.04.032"},{"key":"e_1_3_5_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pediatrneurol.2024.07.008"},{"key":"e_1_3_5_19_1","doi-asserted-by":"publisher","DOI":"10.1001\/archotol.131.8.712"},{"key":"e_1_3_5_20_1","doi-asserted-by":"publisher","DOI":"10.1177\/014556131309200619"},{"key":"e_1_3_5_21_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12957-023-03296-z"},{"key":"e_1_3_5_22_1","doi-asserted-by":"publisher","DOI":"10.1155\/2009\/756395"},{"key":"e_1_3_5_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/EDBK_432242"},{"key":"e_1_3_5_24_1","doi-asserted-by":"publisher","DOI":"10.1177\/17407745231205577"},{"key":"e_1_3_5_25_1","first-page":"45","volume-title":"Neurofibromatosis - diagnosis and treatments","author":"Bassetto F","year":"2023","unstructured":"Bassetto F, Montanari A, Chiara F, et al. Therapeutic approach to plexiform neurofibromas. In: Morgan LR, editor. Neurofibromatosis - diagnosis and treatments. Rijeka (Croatia): IntechOpen; 2023. p. 45\u201383."},{"key":"e_1_3_5_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-3476(97)70092-1"},{"key":"e_1_3_5_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noac146"},{"key":"e_1_3_5_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(12)70414-X"},{"key":"e_1_3_5_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/nou235"},{"key":"e_1_3_5_30_1","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0b013e318207b031"},{"key":"e_1_3_5_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01193-6"},{"key":"e_1_3_5_32_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1605943"},{"key":"e_1_3_5_33_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1912735"},{"key":"e_1_3_5_34_1","unstructured":"US Food & Drug Administration (FDA). FDA approves selumetinib for adults with neurofibromatosis type 1 with symptomatic inoperable plexiform neurofibromas [Internet]. US Food & Drug Administration; 2025 [cited 2025 Nov 19]. Available from:https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-selumetinib-adults-neurofibromatosis-type-1-symptomatic-inoperable-plexiform"},{"key":"e_1_3_5_35_1","unstructured":"Rddad Y. FDA expands selumetinib use to younger children with NF1 tumors [Internet]. HealthCentral LLC; [cited 2025 Sep 23]. Available from: https:\/\/www.oncologynewscentral.com\/drugs\/info\/fda-expands-selumetinib-use-to-younger-children-with-nf1-tumors"},{"key":"e_1_3_5_36_1","doi-asserted-by":"publisher","DOI":"10.1096\/fj.07-8650com"},{"key":"e_1_3_5_37_1","unstructured":"US Food and Drug Administration. GOMEKLI\u2122 (mirdametinib) capsules for oral use and tablets for oral suspension: US prescribing information [Internet]. Stamford (CT): SpringWorks Therapeutics Inc.; 2025 [cited 2025 Dec 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/219379Orig1s000lbl.pdf"},{"key":"e_1_3_5_38_1","unstructured":"US Food and Drug Administration. NDA\/IND multi-disciplinary review and evaluation NDA 219379\/219389 mirdametinib (GOMEKLI) [Internet]. US Food & Drug Administration; 2022 [cited 2025 Dec 21]. Available from: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2025\/219379Orig1s000 219389Orig1s000MultidisciplineR.pdf"},{"key":"e_1_3_5_39_1","first-page":"USA2024","volume-title":"Abstract presented at: The 26th North American ISSX Meeting and 39th JSSX Meeting","author":"Baughman T","year":"2024","unstructured":"Baughman T, Hoang T, Yi Y, et al. The mass balance, recovery, absorption, metabolism, and excretion of [14C]-mirdametinib in healthy male participants after oral dosing. In: Abstract presented at: The 26th North American ISSX Meeting and 39th JSSX Meeting; Honolulu (HI); 2024 Sep 15\u201318. p. USA2024."},{"key":"e_1_3_5_40_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.20.02220"},{"key":"e_1_3_5_41_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrdp.2017.4"},{"key":"e_1_3_5_42_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12010114"},{"key":"e_1_3_5_43_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrc1503"},{"key":"e_1_3_5_44_1","doi-asserted-by":"publisher","DOI":"10.1038\/10533"},{"key":"e_1_3_5_45_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2005.14.415"},{"key":"e_1_3_5_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2004.01.185"},{"key":"e_1_3_5_47_1","unstructured":"Mirdametinib (PD0325901) [Internet]. Selleck Chemicals; [cited 2025 Sep 21]. Available from: https:\/\/www.selleckchem.com\/products\/PD-0325901.html"},{"key":"e_1_3_5_48_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-006-0323-5"},{"key":"e_1_3_5_49_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00109-012-0886-z"},{"key":"e_1_3_5_50_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-08-2223"},{"key":"e_1_3_5_51_1","doi-asserted-by":"publisher","DOI":"10.1593\/neo.09398"},{"key":"e_1_3_5_52_1","doi-asserted-by":"publisher","DOI":"10.1089\/thy.2007.0357"},{"key":"e_1_3_5_53_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-10-0062"},{"key":"e_1_3_5_54_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI60578"},{"key":"e_1_3_5_55_1","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.25546"},{"key":"e_1_3_5_56_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1883"},{"key":"e_1_3_5_57_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00280-011-1620-1"},{"key":"e_1_3_5_58_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-09-1920"},{"key":"e_1_3_5_59_1","doi-asserted-by":"publisher","DOI":"10.1212\/01.wnl.0000435744.57038.af"},{"key":"e_1_3_5_60_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.acra.2017.09.004"},{"key":"e_1_3_5_61_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.24.01034"},{"key":"e_1_3_5_62_1","unstructured":"Natural history study of patients with neurofibromatosis type I [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Dec 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00924196"},{"key":"e_1_3_5_63_1","unstructured":"R115777 to treat children with neurofibromatosis type 1 and progressive plexiform neurofibromas [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Dec 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT00021541"},{"key":"e_1_3_5_64_1","unstructured":"EMA recommends granting a conditional marketing authorisation for mirdametinib [Internet]. European Medicines Agency; 2025 [cited 2025 Dec 22]. Available from: https:\/\/www.esmo.org\/oncology-news\/ema-recommends-granting-a-conditional-marketing-authorisation-for-mirdametinib"},{"key":"e_1_3_5_65_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40487-022-00213-4"},{"key":"e_1_3_5_66_1","volume-title":"SNO Annual Meeting","author":"Anna V","year":"2025","unstructured":"Anna V, Asim BK, Jason C, et al. Efficacy and tolerability of mirdametinib (PD-0325901) in children, adolescents, and young adults with recurrent\/progressive low-grade glioma: update from the SJ901 (NCT04923126) phase 1\/2 clinical trial. Honolulu (HI); 2025. SNO Annual Meeting."},{"key":"e_1_3_5_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jval.2025.04.207"},{"key":"e_1_3_5_68_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(25)00986-9"},{"key":"e_1_3_5_69_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.celrep.2021.109157"},{"key":"e_1_3_5_70_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-3722"},{"key":"e_1_3_5_71_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41389-018-0043-9"},{"key":"e_1_3_5_72_1","unstructured":"Study of the safety and pharmacokinetics of BGB-283 (lifirafenib) and PD-0325901 (mirdametinib) in participants with advanced or refractory solid tumors [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Dec 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT03905148"},{"key":"e_1_3_5_73_1","volume-title":"American Association for Cancer Research Annual Meeting","author":"Solomon B","year":"2023","unstructured":"Solomon B, Gao B, Subbiah V, et al. Abstract CT033: safety, pharmacokinetics, and antitumor activity findings from a phase 1b, open-label, dose-escalation and expansion study investigating RAF dimer inhibitor lifirafenib in combination with MEK inhibitor mirdametinib in patients with advanced or refractory solid tumors. In: American Association for Cancer Research Annual Meeting; Orlando, FL Philadelphia (PA); 2023 Apr 14\u201319."},{"key":"e_1_3_5_74_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.70062"},{"key":"e_1_3_5_75_1","unstructured":"Mirdametinib in patients with advanced NF1-mutant melanoma. ClinicalTrials.gov; 2025 [cited 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07237100"},{"key":"e_1_3_5_76_1","unstructured":"Mirdametinib in histiocytic disorders. 2025 [cited 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06153173?intr=Mirdametinib&rank=2"},{"key":"e_1_3_5_77_1","unstructured":"A study of mirdametinib in combination with palbociclib in people with Liposarcoma. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06843967?intr=Mirdametinib&rank=7"},{"key":"e_1_3_5_78_1","unstructured":"Combination therapy (mirdametinib and Sirolimus) for RAS mutated relapsed refractory multiple myeloma. 2025. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06876142?intr=Mirdametinib&rank=8"},{"key":"e_1_3_5_79_1","unstructured":"Testing the effectiveness of the anti-cancer drug mirdametinib in treating relapsed refractory chronic lymphocytic leukemia [Internet]. ClinicalTrials.gov; 2025 [cited 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT07061951"},{"key":"e_1_3_5_80_1","unstructured":"Clinical trial evaluating the safety and efficacy of chemoimmunotherapy plus short course of MEK inhibitor in first line of treatment of metastatic non squamous non small cell lung adenocarcinoma with PDL1 <50% (IMMUNOMEK) [Internet]. ClinicalTrials.gov; [cited 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT05937906"},{"key":"e_1_3_5_81_1","unstructured":"Phase 1\/2 study of mirdametinib + vinblastine for newly diagnosed\/previously untreated PLGG + activation of MAPK (MIRV) [Internet]. [cited 2025 Dec 11]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT06666348"},{"key":"e_1_3_5_82_1","unstructured":"SJ901: evaluation of mirdametinib in children adolescents and young adults with low-grade glioma. ClinicalTrials.gov; 2025 [cited 2025 Dec 21]. Available from: https:\/\/clinicaltrials.gov\/study\/NCT04923126"},{"key":"e_1_3_5_83_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noab047"},{"key":"e_1_3_5_84_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2303815"},{"key":"e_1_3_5_85_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02668-y"},{"key":"e_1_3_5_86_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-025-02217-6"}],"container-title":["Expert Review of Anticancer Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2645395","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/14737140.2026.2645395","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/14737140.2026.2645395","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,3]],"date-time":"2026-08-03T10:23:31Z","timestamp":1785752611000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/14737140.2026.2645395"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,16]]},"references-count":84,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8,3]]}},"alternative-id":["10.1080\/14737140.2026.2645395"],"URL":"https:\/\/doi.org\/10.1080\/14737140.2026.2645395","relation":{},"ISSN":["1473-7140","1744-8328"],"issn-type":[{"value":"1473-7140","type":"print"},{"value":"1744-8328","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,16]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=iery20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2025-10-04","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-10","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-03-16","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}